A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
-
- STATUS
- Recruiting
Summary
This is an open-label, nonrandomized, Phase 1/2 study to evaluate the safety and tolerability, the PK, the PD, and the efficacy (antianemic activity) of INCB000928 administered alone or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia.
INCB000928 tablets will be administered orally at a starting dose of 50 mg QD in the TGA participant population (monotherapy). The starting dose in combination with ruxolitinib will be determined based on the data from the monotherapy dose escalation. One cycle will be defined as 28 consecutive days; treatment will consist of repeating 28-day cycles. The dose-escalation stages will use a BOIN design to determine the MTD.
For TGB only, the recommended dose for expansion of INCB000928 when administered in combination with ruxolitinib will be determined based on the dose-escalation stage results; efficacy will also be explored. The INCB000928 dose will be escalated using an open-label BOIN design in each defined population, and a safe and tolerable dose (RDE) will be determined in the dose-escalation stages. This RDE will be further explored in the expansion stages for TGB only. Dose escalation and de-escalation will follow the BOIN design algorithm.
For TGB only (Part 2), the expansion stages will aim at further assessing the safety and tolerability of INCB000928, the PK and PD, and determining its antianemic activity when combined with ruxolitinib in participants with transfusion-dependent or symptomatic anemia due to myeloproliferative disorders.
Details
| Condition | Myelofibrosis, Myeloproliferative Disorder, leukemia, Leukemia (Pediatric), Anemia, Leukemia, Red Blood Cell Disorders, Anemia; Non-Hodgkin’s Lymphoma |
|---|---|
| Clinical Study Identifier | TX251101 |
| Last Modified on | 10 May 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer